Database : MEDLINE
Search on : cholangiocarcinoma [Words]
References found : 11656 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1166 go to page                         

  1 / 11656 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29511671
[Au] Autor:Huang Y; Kong Y; Zhang L; He T; Zhou X; Yan Y; Zhang L; Zhou D; Lu S; Zhou J; Zhou L; Xie H; Zheng S; Wang W
[Ad] Address:Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
[Ti] Title:High Expression of ITGA3 Promotes Proliferation and Cell Cycle Progression and Indicates Poor Prognosis in Intrahepatic Cholangiocarcinoma.
[So] Source:Biomed Res Int;2018:2352139, 2018.
[Is] ISSN:2314-6141
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Integrin subunit alpha 3 (ITGA3) interacts with a beta 1 subunit to form a member of the integrin family. Integrins are heterodimeric integral membrane proteins that serve as cell surface adhesion proteins. In this research, we investigated the biological function of this protein in human intrahepatic cholangiocarcinoma (ICC) for the first time. Here, using Western blotting and immunohistochemistry assays, we discovered that ITGA3 was overexpressed in ICC cell lines and ICC patients. Moreover, we found ITGA3 expression correlated with several clinicopathological features, including tumor size, lymph node metastasis, and the TNM stage. Patients with high ITGA3 expression underwent a worse prognosis after complete resection compared with patients with low ITGA3 expression in terms of overall survival. Furthermore, we demonstrated that ITGA3 could significantly promote ICC cell proliferation and cell cycle progression . However, as a classical cell surface adhesion molecule, we found ITGA3 correlated negatively with the migration and invasion of ICC cell lines, which differs from other malignant tumors. Generally, these findings suggest that ITGA3 may play a role as a potential oncogene in ICC and suppression of ITGA3 expression may establish a novel target for guiding the therapy of ICC patients.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Process
[do] DOI:10.1155/2018/2352139

  2 / 11656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29510695
[Au] Autor:Cai X; Li J; Yuan X; Xiao J; Dooley S; Wan X; Weng H; Lu L
[Ad] Address:Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
[Ti] Title:CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma.
[So] Source:J Transl Med;16(1):50, 2018 Mar 06.
[Is] ISSN:1479-5876
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: CD133 is a marker of stem cells as well cancer stem cells. This study investigated the association between CD133 expression in cancer cells and the clinical outcome of non-mucin producing intrahepatic cholangiocarcinoma (ICC). METHODS: Fifty-seven non-mucin producing ICC patients were enrolled in this study. Immunohistochemistry (IHC) and immunofluorescence staining for CD133 as well as other cancer-associated proteins, including cytokeratin 19, TGF-ß1, p-Smad2 and epithelial-mesenchymal transition (EMT) markers S100A4, E-Cadherin and Vimentin were analyzed. RESULTS: IHC staining showed that tumor cells in 52.6% of patients expressed CD133. The CD133 patients had significantly higher metastasis rate than those without CD133 tumor cells (36.7% vs. 10.1%, p = 0.03). The CD133 patients had shorter overall and disease-free survival time as compared to the CD133 patients. Furthermore, 90.9% of CD133 patients developed cancer recurrence, as compared to 64.3% of CD133 patients (p = 0.02). As compared to CD133 patients, tumor cells in CD133 patients demonstrated high levels of TGF-ß/p-Smad2 as well as EMT-like alteration, characterized by loss of E-Cadherin and expression of Vimentin and S100A4. CONCLUSIONS: CD133 expression in ICC tumor cells indicates poor prognosis of the disease and might be associated with TGF-ß related EMT alterations.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Data-Review
[do] DOI:10.1186/s12967-018-1423-9

  3 / 11656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29486282
[Au] Autor:Li X; Xu A; Li H; Zhang B; Cao B; Huang J
[Ad] Address:Experimental Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China; National Clinical Research Center for Digestive Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
[Ti] Title:Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells.
[So] Source:Biochim Biophys Acta;1864(5 Pt A):1693-1701, 2018 Feb 24.
[Is] ISSN:0006-3002
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Although apatinib has been demonstrated with potential antitumor activity in multiple solid tumors, the underlying mechanism of apatinib for the treatment of hepatocellular carcinoma (HCC) remains unclear. In the present study, we explored if there are any direct suppression effects of apatinib on HCC cells and its relevant targets. We investigated the effect of apatinib on viability of five HCC cell lines and an intrahepatic cholangiocarcinoma cell line, and colony formation, apoptosis and migration of representative HCC cells in vitro; and HCC progression in a xenograft mouse model. Using a phospho-receptor tyrosine kinase pathway array with 49 different tyrosine kinases, we screened and verified the tyrosine kinase targets involved in apatinib response. Apatinib treatment significantly inhibited HCC cell viability, proliferation, colony formation, and migration, and enhanced cell apoptosis in a concentration-dependent manner (p < 0.05). Furthermore, apatinib showed a favorable anti-tumor growth effect (71% of inhibition ratio, p < 0.05) in an established human HCC xenograft mice model with good safety. RTK pathway arrays and western blots analysis demonstrated that apatinib significantly downregulated the phosphorylation levels of several tyrosine kinase receptors, particularly PDGFR-α and IGF-IR, and inhibited Akt phosphorylation. These data suggest that the apatinib may have a direct anti-HCC effect as a direct multi-target RTK inhibitor of HCC cells and a promising potentiality in HCC clinical therapies.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  4 / 11656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29284072
[Au] Autor:Krasnick BA; Jin LX; Davidson JT; Sanford DE; Ethun CG; Pawlik TM; Poultsides GA; Tran T; Idrees K; Hawkins WG; Chapman WC; Doyle MBM; Weber SM; Strasberg SM; Salem A; Martin RCG; Isom CA; Scoggins C; Schmidt CR; Shen P; Beal E; Hatzaras I; Shenoy R; Maithel SK; Fields RC
[Ad] Address:Department of Surgery, Washington University School of Medicine, St Louis, Missouri.
[Ti] Title:Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium.
[So] Source:J Surg Oncol;, 2017 Dec 28.
[Is] ISSN:1096-9098
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Curative-intent treatment for localized hilar cholangiocarcinoma (HC) requires surgical resection. However, the effect of adjuvant therapy (AT) on survival is unclear. We analyzed the impact of AT on overall (OS) and recurrence free survival (RFS) in patients undergoing curative resection. METHODS: We reviewed patients with resected HC between 2000 and 2015 from the ten institutions participating in the U.S. Extrahepatic Biliary Malignancy Consortium. We analyzed the impact of AT on RFS and OS. The probability of RFS and OS were calculated in the method of Kaplan and Meier and analyzed using multivariate Cox regression analysis. RESULTS: A total of 249 patients underwent curative resection for HC. Patients who received AT and those who did not had similar demographic and preoperative features. In a multivariate Cox regression analysis, AT conferred a significant protective effect on OS (HR 0.58, P = 0.013), and this was maintained in a propensity matched analysis (HR 0.66, P = 0.033). The protective effect of AT remained significant when node negative patients were excluded (HR 0.28, P = 0.001), while it disappeared (HR 0.76, P = 0.260) when node positive patients were excluded. CONCLUSIONS: AT should be strongly considered after curative-intent resection for HC, particularly in patients with node positive disease.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:Publisher
[do] DOI:10.1002/jso.24836

  5 / 11656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29523614
[Au] Autor:Abeysinghe V; Sundararajan S; Delriviere L; Tibballs J
[Ad] Address:General Surgery, Royal Perth Hospital, Perth, Western Australia, Australia.
[Ti] Title:Selective internal radiation therapy (SIRT) with yttrium-90 microspheres for unresectable intrahepatic cholangiocarcinoma.
[So] Source:BMJ Case Rep;2018, 2018 Mar 09.
[Is] ISSN:1757-790X
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Unresectableintrahepaticcholangiocarcinoma has a very poor prognosis despite various treatment options. The case presented describes the diagnostic challenges of a young pregnant woman with unresectable cholangiocarcinoma. The current treatment options for cholangiocarcinoma have limited evidence and high recurrence rate. Given the young age of this patient, selective internal radiotherapy was trialled with traditional chemotherapy with a clinically significant result. This case highlights the delays when diagnosing cholangiocarcinoma in younger patients and the possibility of selective internal radiation therapy in combination with chemotherapy as a potential first-line treatment for a complete response in unresectable disease.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:In-Process

  6 / 11656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29486176
[Au] Autor:Kim JY; Yong TS; Rim HJ; Chai JY; Min DY; Eom KS; Sohn WM; Lim JH; Choi D; Insisiengmay S; Phommasack B; Insisiengmay B
[Ad] Address:Department of Environmental Medical Biology, Institute of Tropical Medicine, Arthropods of Medical Importance Resource Bank, Yonsei University College of Medicine, Seoul 03722, Republic of Korea; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Rep
[Ti] Title:Ultrasonographic investigation of cholangiocarcinoma in Lao PDR.
[So] Source:Acta Trop;182:128-134, 2018 Feb 24.
[Is] ISSN:1873-6254
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Opisthorchis viverrini is a group 1 carcinogen that causes cholangiocarcinoma (CCA). Although opisthorchiasis is known to be severely endemic to several areas along the Mekong River in Lao PDR, the CCA status of residents of this region is still under investigation. In this study, we analyzed the results of abdominal ultrasonography (US) performed on 6113 residents in 9 provinces (Vientiane Municipality, Savannakhet, Phongsaly, Khammouane, Saravane, Champasak, Vientiane, Xieng Khuouang, and Luang Prabang provinces) of Lao PDR from 2007 to 2011. Overall, 51 cases (0.83%) were detected with suspected CCA. The CCA rates in Vientiane Municipality and in Savannakhet and Khammouane provinces were 1.45%, 1.58%, and 1.09%, respectively. However, in the other 6 provinces, the rate of CCA averaged only 0.26%. In the 3 provinces with higher rates of CCA, bile duct dilatation (grade ≥ 2) was also significantly more prevalent (P < 0.0001). These results are concordant with previous reports showing a higher endemicity of opisthorchiasis in Vientiane Municipality and in Savannakhet and Khammouane provinces.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher

  7 / 11656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29454098
[Au] Autor:Pak LM; Chakraborty J; Gonen M; Chapman WC; Do RKG; Groot Koerkamp B; Verhoef K; Lee SY; Massani M; van der Stok EP; Simpson AL; Memorial Sloan Kettering Cancer Center Hepatopancreatobiliary Service
[Ad] Address:Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
[Ti] Title:Quantitative Imaging Features and Postoperative Hepatic Insufficiency: A Multi-Institutional Expanded Cohort.
[So] Source:J Am Coll Surg;, 2018 Feb 15.
[Is] ISSN:1879-1190
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Post-hepatectomy liver insufficiency (PHLI) is a significant cause of morbidity and mortality after liver resection. Quantitative imaging analysis using CT scans measures variations in pixel intensity related to perfusion. A preliminary study demonstrated a correlation between quantitative imaging features of the future liver remnant (FLR) parenchyma from preoperative CT scans and PHLI. The objective of this study was to explore the potential application of quantitative imaging analysis in PHLI in an expanded, multi-institutional cohort. STUDY DESIGN: We retrospectively identified patients from 5 high-volume academic centers who developed PHLI after major hepatectomy, and matched them to control patients without PHLI (by extent of resection, preoperative chemotherapy treatment, age [±5 years], and sex). Quantitative imaging features were extracted from the FLR in the preoperative CT scan, and the most discriminatory features were identified using conditional logistic regression. Percent remnant liver volume (RLV) was defined as follows: (FLR volume)/(total liver volume) × 100. Significant clinical and imaging features were combined in a multivariate analysis using conditional logistic regression. RESULTS: From 2000 to 2015, 74 patients with PHLI and 74 matched controls were identified. The most common indications for surgery were colorectal liver metastases (53%), hepatocellular carcinoma (37%), and cholangiocarcinoma (9%). Two CT imaging features (FD1_4: image complexity; ACM1_10: spatial distribution of pixel intensity) were strongly associated with PHLI and remained associated with PHLI on multivariate analysis (p = 0.018 and p = 0.023, respectively), independent of clinical variables, including preoperative bilirubin and %RLV. CONCLUSIONS: Quantitative imaging features are independently associated with PHLI and are a promising preoperative risk stratification tool.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  8 / 11656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29520653
[Au] Autor:Aloia TA
[Ad] Address:Department of Surgical Oncology, University of Texas-MD Anderson Cancer Center, Houston, TX, USA. taaloia@mdanderson.org.
[Ti] Title:Precision Hilar Cholangiocarcinoma Surgery.
[So] Source:Ann Surg Oncol;, 2018 Mar 08.
[Is] ISSN:1534-4681
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:EDITORIAL
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1245/s10434-018-6416-7

  9 / 11656 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29520523
[Au] Autor:Yamaguchi T; Kato K; Nagashima K; Iwasa S; Honma Y; Takashima A; Hamaguchi T; Ito Y; Itami J; Boku N; Higuchi K
[Ad] Address:Cancer Chemotherapy Center, Osaka Medical College Hospital, Osaka Medical College, 2-7 Daigaku machi, Takatsuki, Osaka, 569-8686, Japan. yamagu.toshifumi@gmail.com.
[Ti] Title:Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma.
[So] Source:Int J Clin Oncol;, 2018 Mar 08.
[Is] ISSN:1437-7772
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:BACKGROUND: While the standard treatment for stage II-III (non-T4) esophageal squamous cell carcinoma (ESCC) is neoadjuvant therapy followed by esophagectomy, definitive chemoradiation therapy (dCRT) is an option to treat ESCC patients who reject or may not tolerate surgical treatment. Second primary malignancy (SPM) is a problem for long-term survivors after achieving complete response (CR) by dCRT. METHODS: The source of the subjects in this study was the patients with stage II/III (excluding T4 disease) ESCC (UICC6th) who underwent dCRT from 2000 to 2011 at the National Cancer Center Hospital, Japan. SPM, defined as malignancy newly detected at different site from the initial disease, was checked in patients who achieved CR by the initial dCRT. RESULTS: Among the 285 patients with stage II/III (excluding T4 disease) ESCC who underwent dCRT, 185 patients achieved CR. SPM was detected in 49 patients (median time to developing SPM, 41.5 months), accounting for 19.3% (95% CI 0.137-0.257) as the 5-year cumulative risk of SPM. SPMs were head and neck cancer (n = 12), gastric cancer (n = 12), esophageal cancer (n = 7), lung cancer (n = 5), colon cancer (n = 4), diffuse large B-cell lymphoma (n = 3), bladder cancer (n = 2), small intestinal cancer (n = 1), cholangiocarcinoma (n = 1), malignant melanoma (n = 1), and breast cancer (n = 1). There were no significant differences in baseline characteristics between the patients who developed SPM (n = 49) and others (n = 136). CONCLUSIONS: Because second primary malignancy developed often after achieving CR by dCRT for ESCC, it should be followed carefully.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1007/s10147-018-1258-7

  10 / 11656 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29520041
[Au] Autor:Petrick JL; Campbell PT; Koshiol J; Thistle JE; Andreotti G; Beane-Freeman LE; Buring JE; Chan AT; Chong DQ; Doody MM; Gapstur SM; Gaziano JM; Giovannucci E; Graubard BI; Lee IM; Liao LM; Linet MS; Palmer JR; Poynter JN; Purdue MP; Robien K; Rosenberg L; Schairer C; Sesso HD; Sinha R; Stampfer MJ; Stefanick M; Wactawski-Wende J; Zhang X; Zeleniuch-Jacquotte A; Freedman ND; McGlynn KA
[Ad] Address:Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. jessica.petrick@nih.gov.
[Ti] Title:Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project.
[So] Source:Br J Cancer;, 2018 Mar 09.
[Is] ISSN:1532-1827
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: While tobacco and alcohol are established risk factors for hepatocellular carcinoma (HCC), the most common type of primary liver cancer, it is unknown whether they also increase the risk of intrahepatic cholangiocarcinoma (ICC). Thus, we examined the association between tobacco and alcohol use by primary liver cancer type. METHODS: The Liver Cancer Pooling Project is a consortium of 14 US-based prospective cohort studies that includes data from 1,518,741 individuals (HCC n = 1423, ICC n = 410). Multivariable-adjusted hazards ratios (HRs) and 95% confidence intervals (CI) were estimated using proportional hazards regression. RESULTS: Current smokers at baseline had an increased risk of HCC (hazard ratio (HR) = 1.86, 95% confidence interval (CI): 1.57-2.20) and ICC (HR = 1.47, 95% CI: 1.07-2.02). Among individuals who quit smoking >30 years ago, HCC risk was almost equivalent to never smokers (HR = 1.09, 95% CI: 0.74-1.61). Compared to non-drinkers, heavy alcohol consumption was associated with an 87% increased HCC risk (HR = 1.87, 95% CI: 1.41-2.47) and a 68% increased ICC risk (HR = 1.68, 95% CI: 0.99-2.86). However, light-to-moderate alcohol consumption of <3 drinks/day appeared to be inversely associated with HCC risk (HR = 0.77, 95% CI: 0.67-0.89; HR = 0.57, 95% CI: 0.44-0.73; HR = 0.71, 95% CI: 0.58-0.87), but not ICC. CONCLUSIONS: These findings suggest that, in this relatively healthy population, smoking cessation and light-to-moderate drinking may reduce the risk of HCC.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1038/s41416-018-0007-z


page 1 of 1166 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information